Lupin Forays into non-exclusive patent licensing agreement with Takeda

Leading pharmaceutical company Lupin Limited has revealed a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to sell vonoprazan tablets in India. Lupin will be launching their new drug, Lupivon, in two different dosages of 10 mg and 20 mg.

According to this agreement, Takeda has given Lupin non-exclusive rights to use vonoprazan patents for commercial purposes in India.

"We are very pleased to commercialize vonoprazan, a novel treatment option for acid peptic disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients,” said, Rajeev Sibal, president India region formulations, Lupin.   Acid peptic disorder (APD), such as gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), is commonly found in India. GERD is found in 5% to 28.5% of the population, while PUD affects approximately 8% of people. Old age, high BMI, non-vegetarian diet, tea/coffee consumption, smoking, and alcohol intake are all risk factors for GERD.

Vonoprazan is a new type of medication known as a potassium-competitive acid blocker (P-CAB). In contrast to conventional acid reducers such as PPIs, vonoprazan provides distinctive qualities such as full proton pump inhibition after initial use, extended effectiveness for controlling nighttime acid breakthrough, and the ability to be taken regardless of meals.